BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex Pharmaceuticals (VRTX) announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral ...

Radiculopathy, or a pinched nerve in the spine, can cause symptoms, including pain, weakness, and numbness. Pain relievers, steroids, and physical therapy can help treat radiculopathy. A doctor may ...

CNV1014802 showed a statistically significant reduction in pain Well tolerated and effective therapeutic dose without any requirement for dose titration Performance potentially broadens the use in ...

To learn more about James' injury, The Sporting News spoke with medical expert Dr. Michael S. George of the KSF Orthopaedic ...

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

BOSTON-- (BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...